Philips A, Teyssier C, Galtier F, Rivier-Covas C, Rey J M, Rochefort H, Chalbos D
Institut National de la Santé et de la Recherche Médicale Hormones and Cancer (U 148), Montpellier, France.
Mol Endocrinol. 1998 Jul;12(7):973-85. doi: 10.1210/mend.12.7.0133.
We compared the effect of estradiol on activator protein-1 (AP-1) activity in estrogen receptor positive (ER alpha+) and estrogen receptor negative (ER alpha-) human breast cancer cell lines transiently transfected with the AP-1-responsive reporter plasmid AP-1-TK-CAT and an ER alpha expression vector. While estradiol increased AP-1 activity in the ER alpha+ cell lines MCF7, ZR75.1, and T47D, it decreased (MDA-MB231 and BT20 cells) or had no significant effect (MDA-MB435 cells) on AP-1-mediated transcription in ER alpha- cells. Estradiol also inhibited AP-1 activity in ER alpha-MDA-MB231 cells stably transfected with ER alpha and in which ER alpha levels are close to those found in MCF7. Use of ER alpha mutant expression vectors demonstrated that the DNA-binding domain of ER alpha was needed for stimulation or inhibition of AP-1 activity by estradiol but suggested that ER alpha binding to estrogen-responsive elements was not required for these effects. Changes in regulation paralleled quantitative and qualitative changes in protein binding to AP-1 sites, as demonstrated by gel shift assay: protein binding was greater and DNA/protein complexes migrated faster for ER alpha--than for ER alpha+ cells. In fact, by Northern blot, a high level of Fra-1 mRNA was found in BT20 and MDA-MB231 cells as compared with ER alpha+ cells, and MDA-MB435 cells showed an intermediary level of expression. The differential expression of Fra-1 in MCF7 and MDA-MB231 cells was confirmed at the protein level by supershift experiments. In addition, overexpression of Fra-1 in MCF7 cells decreased the positive effect of estradiol while inhibition of Fra-1 expression in MDA-MB231 cells, by transient transfection of the Fra-1 antisense expression vector, abolished the negative effect of the hormone. In conclusion, we demonstrated that ER alpha- breast cancer cell lines differ from ER+ cells by a high level of AP-1 DNA-binding activity due, at least in part, to high Fra-1 constitutive expression. High Fra-1 concentration is crucial for the negative regulation of AP-1 activity by estradiol and thus may take part in estradiol-induced inhibition of cell proliferation in ER alpha- breast cancer cells transfected with ER alpha expression construct.
我们比较了雌二醇对瞬时转染了AP-1反应性报告质粒AP-1-TK-CAT和雌激素受体α(ERα)表达载体的雌激素受体阳性(ERα+)和雌激素受体阴性(ERα-)人乳腺癌细胞系中活化蛋白-1(AP-1)活性的影响。虽然雌二醇增加了ERα+细胞系MCF7、ZR75.1和T47D中的AP-1活性,但它对ERα-细胞中AP-1介导的转录有降低作用(MDA-MB231和BT20细胞)或无显著影响(MDA-MB435细胞)。雌二醇还抑制了稳定转染ERα且ERα水平接近MCF7中水平的ERα-MDA-MB231细胞中的AP-1活性。使用ERα突变体表达载体表明,ERα的DNA结合结构域是雌二醇刺激或抑制AP-1活性所必需的,但提示这些效应不需要ERα与雌激素反应元件结合。如凝胶迁移试验所示,调节变化与蛋白质结合到AP-1位点的定量和定性变化平行:与ERα+细胞相比,ERα-细胞中蛋白质结合更强,DNA/蛋白质复合物迁移更快。事实上,通过Northern印迹法,与ERα+细胞相比,在BT20和MDA-MB231细胞中发现高水平的Fra-1 mRNA,而MDA-MB435细胞显示出中间表达水平。通过超迁移实验在蛋白质水平证实了Fra-1在MCF7和MDA-MB231细胞中的差异表达。此外,在MCF7细胞中过表达Fra-1降低了雌二醇的阳性作用,而通过瞬时转染Fra-1反义表达载体抑制MDA-MB231细胞中Fra-1的表达则消除了激素的阴性作用。总之,我们证明ERα-乳腺癌细胞系与ER+细胞的不同之处在于高水平的AP-1 DNA结合活性,这至少部分归因于Fra-1的高组成型表达。高Fra-1浓度对于雌二醇对AP-1活性的负调节至关重要,因此可能参与了用ERα表达构建体转染的ERα-乳腺癌细胞中雌二醇诱导的细胞增殖抑制。